A 48-year-old man with acromegaly is started on octreotide long-acting release. Through which somatostatin receptor subtype does this drug primarily mediate its therapeutic effect?
- A SSTR1
- B SSTR2 ✓
- C SSTR4
- D SSTR5
Correct answer: B. SSTR2
Explanation
Octreotide and lanreotide are somatostatin analogues with high affinity for SSTR2, which is the dominant subtype mediating GH suppression in somatotroph adenomas. SSTR5 contributes but is secondary. SSTR1 and SSTR4 have minimal role in GH inhibition. Pegvisomant, by contrast, is a GH receptor antagonist and does not act via somatostatin receptors at all.
Reference: Williams Textbook of Endocrinology, 14th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.